{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:42:42Z","timestamp":1790710962512,"version":"4.1.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.nucmedbio.2021.03.007","type":"journal-article","created":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T00:11:01Z","timestamp":1616803861000},"page":"80-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["AAZTA5-squaramide ester competing with DOTA-, DTPA- and CHX-A\u2033-DTPA-analogues: Promising tool for 177Lu-labeling of monoclonal antibodies under mild conditions"],"prefix":"10.1016","volume":"96-97","author":[{"given":"Benedikt","family":"Klasen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Euy Sung","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"R\u00f6sch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0005","article-title":"Risk evaluation and mitigation strategy for approved therapeutic antibodies","volume":"1","author":"Cai","year":"2014","journal-title":"MOJ Immunol"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0010","doi-asserted-by":"crossref","DOI":"10.15406\/moji.2016.03.00087","article-title":"Therapeutic monoclonal antibodies approved by FDA in 2015","volume":"3","author":"Cai","year":"2016","journal-title":"MOJ Immunol"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0015","doi-asserted-by":"crossref","DOI":"10.15406\/moji.2017.05.00145","article-title":"Therapeutic monoclonal antibodies approved by FDA in 2016","volume":"5","author":"Cai","year":"2017","journal-title":"MOJ Immunol"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0020","article-title":"Therapeutic monoclonal antibodies approved by FDA in 2017","volume":"6","author":"Cai","year":"2018","journal-title":"MOJ Immunol"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0025","first-page":"85","article-title":"2018 FDA drug approvals","volume":"18","author":"Mullard","year":"2019","journal-title":"Nat Rev"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0030","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1007\/s11033-018-4427-x","article-title":"Monoclonal antibodies in cancer immunotherapy","volume":"45","author":"Kimiz-Gebologlu","year":"2018","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0035","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2019.1703531","article-title":"Antibodies to watch in 2020","volume":"12","author":"Kaplon","year":"2020","journal-title":"MAbs"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0040","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/00007890-198904000-00008","article-title":"Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients","volume":"47","author":"Abramowicz","year":"1989","journal-title":"Transplantation"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0045","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.nucmedbio.2007.04.001","article-title":"Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view","volume":"34","author":"Boswell","year":"2007","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0050","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s00259-011-1731-2","article-title":"99mTc-besilesomab (Scintimun\u00ae) in peripheral osteomyelitis: comparison with 99mTc-labelled white blood cells","volume":"38","author":"Richter","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0055","first-page":"155","article-title":"Indium-111 satumomab pendetide: the first FDA-approved monoclonal antibody for tumor imaging","volume":"26","author":"Bohdiewicz","year":"1998","journal-title":"J Nucl Med Technol"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0060","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1159\/000151565","article-title":"Technetium-99m-labelled sulesomab (LeukoScan) in the evaluation of soft tissue infections","volume":"17","author":"Quigley","year":"2008","journal-title":"Med Princ Pract"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0065","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1200\/JCO.1996.14.8.2295","article-title":"Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab\u2032 antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial","volume":"14","author":"Moffat","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0070","first-page":"S19","article-title":"ProstaScint(R) scan: contemporary use in clinical practice","volume":"6","author":"Taneja","year":"2004","journal-title":"Rev Urol"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0075","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4103\/1450-1147.163259","article-title":"Indium-111 capromab pendetide (ProstaScint\u00ae) demonstrates renal cell carcinoma and aortocaval nodal metastases from prostate adenocarcinoma","volume":"14","author":"Rizvi","year":"2015","journal-title":"World J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0080","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/00003072-199709000-00007","article-title":"Clinical experience with Tc-99m nofetumomab merpentan (verluma) radioimmunoscintigraphy","volume":"22","author":"Breitz","year":"1997","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0085","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2217\/imt.10.114","article-title":"Cancer radioimmunotherapy","volume":"3","author":"Sharkey","year":"2011","journal-title":"Immunotherapy"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/492061","article-title":"Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies","volume":"2014","author":"Kawashima","year":"2014","journal-title":"Sci World J"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0095","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1631\/jzus.B1400131","article-title":"Therapeutic radionuclides in nuclear medicine: current and future prospects","volume":"15","author":"Yeong","year":"2014","journal-title":"J Zhejiang Univ Sci B"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0100","series-title":"Methods Mol. Biol","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/978-1-61779-974-7_38","article-title":"Radiolabeled antibodies for cancer imaging and therapy","volume":"vol. 907","author":"Barbet","year":"2012"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0105","doi-asserted-by":"crossref","first-page":"83S","DOI":"10.2967\/jnumed.116.186940","article-title":"Theranostics using antibodies and antibody-related therapeutics","volume":"58","author":"Moek","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0110","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1051\/medsci\/200925121039","article-title":"Les anticorps radiomarqu\u00e9s pour le traitement des cancers","volume":"25","author":"Barbet","year":"2009","journal-title":"M\u00e9decine\/Sciences"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0115","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/jlcr.3590","article-title":"Chemical aspects of metal ion chelation in the synthesis and application antibody-based radiotracers","volume":"61","author":"Boros","year":"2018","journal-title":"J Label Compd Radiopharm"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0120","first-page":"3263","article-title":"Advantage of lutetium-177 versus radioiodine immunoconjugate in targeted radionuclide therapy of B-cell tumors","volume":"34","author":"Repetto-Llamazares","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0125","first-page":"111","article-title":"Improved iodine radiolabels for monoclonal antibody therapy","volume":"63","author":"Stein","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0130","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s13139-014-0315-z","article-title":"Production of 177Lu for targeted radionuclide therapy: available options","volume":"49","author":"Dash","year":"2015","journal-title":"Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0135","first-page":"1310","article-title":"Treatment with 177Lu-DODOTAT of patients with relapse of neuroendocrine tumors after treatment with 90Y-DODOTAT","volume":"46","author":"Forrer","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0140","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/MNM.0000000000000874","article-title":"177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update","volume":"39","author":"Demirci","year":"2018","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0145","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000496335","article-title":"Expanding the indication for novel theranostic 177Lu-dotatate peptide receptor radionuclide therapy: proof-of-concept of PRRT in Merkel cell cancer","volume":"12","author":"Kasi","year":"2019","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0150","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000402936","article-title":"Peptide receptor radionuclide therapy of neuroendocrine tumors","volume":"44","author":"Bodei","year":"2015","journal-title":"Front Horm Res"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0155","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1039\/C3CS60304K","article-title":"Matching chelators to radiometals for radiopharmaceuticals","volume":"43","author":"Price","year":"2014","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0160","first-page":"1224","article-title":"Biodistribution and therapeutic efficacy of 125\/131I-, 186Re-, 88\/90Y-, or 177Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin","volume":"45","author":"Koppe","year":"2004","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0165","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0969-8051(97)00151-0","article-title":"Samarium-153 and Lutetium-177 chelation properties of selected macrocyclic and acyclic ligands","volume":"25","author":"Stimmel","year":"1998","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0170","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0969-8051(02)00294-9","article-title":"In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications","volume":"29","author":"Milenic","year":"2002","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0175","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.nucmedbio.2010.04.020","article-title":"Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands","volume":"37","author":"Hens","year":"2010","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0180","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00259-003-1142-0","article-title":"Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities","volume":"30","author":"Breeman","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0185","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0020-1693(94)03964-X","article-title":"Stability constants of the lanthanide(III)-1,4,7,10-tetraazacyclododecane-N,N\u2032,N\u2033,N\u2034-tetraacetate complexes","volume":"221","author":"T\u00f3th","year":"1994","journal-title":"Inorganica Chim Acta"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0190","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1021\/ic00006a021","article-title":"Thermodynamic and kinetic studies of lanthanide complexes of 1,4,7,10,13-pentaazacyclopentadecane-N,N\u2032,N\u2033,N\u2034,N\u2034\u2032-pentaacetic acid and 1,4,7,10,13,16-hexaazacyclooctadecane-N,N\u2032,N\u2033,N\u2034,N\u2034\u2032,N\u2034\u2033-hexaacetic acid","volume":"30","author":"Kodama","year":"1991","journal-title":"Inorg Chem"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0195","doi-asserted-by":"crossref","first-page":"12707","DOI":"10.1021\/ja4049493","article-title":"H4octapa-trastuzumab: versatile acyclic chelate system for 111In and 177Lu imaging and therapy","volume":"135","author":"Price","year":"2013","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0200","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.nucmedbio.2016.06.004","article-title":"A comparative evaluation of the chelators H4octapa and CHX-A\u2033-DTPA with the therapeutic radiometal 90Y","volume":"43","author":"Price","year":"2016","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0205","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1007\/BF00285586","article-title":"Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1 B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA)","volume":"21","author":"Camera","year":"1994","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0210","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0969-8051(96)00130-8","article-title":"Copper radionuclides and radiopharmaceuticals in nuclear medicine","volume":"23","author":"Blower","year":"1996","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0215","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0020-1693(00)80229-7","article-title":"Stabilities of trivalent metal ion complexes of the tetraacetate derivatives of 12-, 13- and 14-membered tetraazamacrocycles","volume":"190","author":"Clarke","year":"1991","journal-title":"Inorganica Chim Acta"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0220","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1021\/bc010134h","article-title":"Comparison of yttrium and indium complexes of DOTA-BA and DOTA-MBA: models for 90Y- and 111In-labeled DOTA-biomolecule conjugates","volume":"13","author":"Liu","year":"2002","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0225","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1021\/bc00032a010","article-title":"Yttrium-90 chelation properties of tetraazatetraacetic acid macrocycles, diethylenetriaminepentaacetic acid analogs, and a novel terpyridine acyclic chelator","volume":"6","author":"Stimmel","year":"1995","journal-title":"Bioconjug Chem"},{"issue":"53","key":"10.1016\/j.nucmedbio.2021.03.007_bb0230","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1039\/p29910000087","volume":"2","author":"Broan","year":"1991","journal-title":"J Chem Soc Perkin Trans"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0235","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1158\/1078-0432.CCR-03-0800","article-title":"Alpha-particle emitting atomic generator (actinium-225)-labeled trastuzumab (Herceptin) targeting of breast cancer spheroids: efficacy versus HER2\/neu expression","volume":"10","author":"Ballangrud","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0240","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1021\/cr500171e","article-title":"Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications","volume":"115","author":"Banerjee","year":"2015","journal-title":"Chem Rev"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0245","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1021\/cr00078a006","article-title":"Reaction mechanisms in the radiolysis of peptides, polypeptides, and proteins","volume":"87","author":"Garrison","year":"1987","journal-title":"Chem Rev"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0250","first-page":"1898","article-title":"89Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals 90Y and 177Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab","volume":"46","author":"Perk","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0255","first-page":"441","article-title":"Synthesis and stability test of radioimmunoconjugate 177Lu-DOTA-F(ab\u2019)2-trastuzumab for theranostic agent of HER2 positive breast cancer","volume":"9","author":"Hermanto","year":"2016","journal-title":"J Radiat Res Appl Sci"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0260","first-page":"285","article-title":"Labelling chemistry and characterization of [90Y\/177Lu]-DOTA-ZHER2:342-3 affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma","volume":"19","author":"Fortin","year":"2007","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0265","doi-asserted-by":"crossref","first-page":"961","DOI":"10.2967\/jnumed.112.110700","article-title":"Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein","volume":"54","author":"Orlova","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0270","first-page":"544","article-title":"An approach for conjugation of 177Lu-DOTA-SCN-rituximab (biosim) & its evaluation for radioimmunotherapy of relapsed & refractory B-cell non Hodgkins lymphoma patients","volume":"139","author":"Thakral","year":"2014","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0275","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2174\/1874471008666141215151253","article-title":"Standardization of procedures for the preparation of 177Lu- and 90Y-labeled DOTA-rituximab based on the freeze-dried kit formulation","volume":"8","author":"Wojdowska","year":"2015","journal-title":"Curr Radiopharm"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0280","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/jlcr.1780","article-title":"Synthesis and biodistribution studies of 177Lu-trastuzumab as a therapeutic agent in the breast cancer mice model","volume":"53","author":"Rasaneh","year":"2010","journal-title":"J Label Compd Radiopharm"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0285","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13550-015-0154-7","article-title":"Influence of a novel, versatile bifunctional chelator on theranostic properties of a minigastrin analogue","volume":"5","author":"Pfister","year":"2015","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0290","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1002\/chem.200801803","article-title":"Equilibrium and kinetic properties of the lanthanoids(III) and various divalent metal complexes of the heptadentate ligand AAZTA","volume":"15","author":"Baranyai","year":"2009","journal-title":"Chem A Eur J"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0295","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1002\/anie.201611207","article-title":"AAZTA: an ideal chelating agent for the development of 44Sc PET imaging agents","volume":"56","author":"Nagy","year":"2017","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0300","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1039\/c0cs00199f","article-title":"The synthesis and application of polyamino polycarboxylic bifunctional chelating agents","volume":"40","author":"Lattuada","year":"2011","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0305","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s41181-019-0068-1","article-title":"AAZTA5\/AAZTA5-TOC: synthesis and radiochemical evaluation with 68Ga, 44Sc and 177Lu","volume":"4","author":"Sinnes","year":"2019","journal-title":"EJNMMI Radiopharm Chem"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0310","doi-asserted-by":"crossref","first-page":"108867","DOI":"10.1016\/j.apradiso.2019.108867","article-title":"Synthesis and labeling of a squaric acid containing PSMA-inhibitor coupled to AAZTA5 for versatile labeling with 44Sc, 64Cu, 68Ga and 177Lu","volume":"156","author":"Greifenstein","year":"2020","journal-title":"Appl Radiat Isot"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0315","doi-asserted-by":"crossref","first-page":"7588","DOI":"10.1021\/ic0489692","article-title":"[Gd-AAZTA]-: a new structural entry for an improved generation of MRI contrast agents","volume":"43","author":"Aime","year":"2004","journal-title":"Inorg Chem"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0320","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1039\/C2CC37544C","article-title":"Structure and stability of hexadentate complexes of ligands based on AAZTA for efficient PET labelling with gallium-68","volume":"49","author":"Waldron","year":"2013","journal-title":"Chem Commun"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0325","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/cmdc.201200043","article-title":"Synthesis of Gd and 68Ga complexes in conjugation with a conformationally optimized RGD sequence as potential MRI and PET tumor-imaging probes","volume":"7","author":"Manzoni","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0330","doi-asserted-by":"crossref","first-page":"8220","DOI":"10.1039\/c3cs60153f","article-title":"Be squared: expanding the horizon of squaric acid-mediated conjugations","volume":"42","author":"Wurm","year":"2013","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0335","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/cber.19911240539","article-title":"Squaric acid diethyl ester: a new coupling reagent for the formation of drug biopolymer conjugates. Synthesis of squaric acid ester amides and diamides","volume":"124","author":"Tietze","year":"1991","journal-title":"Chem Ber"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0340","doi-asserted-by":"crossref","first-page":"11889","DOI":"10.1039\/C6CC05961A","article-title":"A desferrioxamine B squaramide ester for the incorporation of zirconium-89 into antibodies","volume":"52","author":"Rudd","year":"2016","journal-title":"Chem Commun"},{"key":"10.1016\/j.nucmedbio.2021.03.007_bb0345","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1039\/c3ob40287h","article-title":"Conformational analysis and synthetic approaches to polydentate perhydro-diazepine ligands for the complexation of gallium(iii)","volume":"11","author":"Parker","year":"2013","journal-title":"Org Biomol Chem"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805121000500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805121000500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T04:29:40Z","timestamp":1760848180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805121000500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":69,"alternative-id":["S0969805121000500"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2021.03.007","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AAZTA5-squaramide ester competing with DOTA-, DTPA- and CHX-A\u2033-DTPA-analogues: Promising tool for 177Lu-labeling of monoclonal antibodies under mild conditions","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2021.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}